City
Epaper

50 pc tariffs by US bad policy move, India must continue to protect its farmers: SBI report

By IANS | Updated: August 8, 2025 10:44 IST

New Delhi, Aug 8 Imposition of 25 per cent penalty on goods trade with India, with a proposition ...

Open in App

New Delhi, Aug 8 Imposition of 25 per cent penalty on goods trade with India, with a proposition of additional 25 per cent on the world’s largest democracy, can be a bad policy decision for the US and its people, an SBI Research report said on Friday.

On the other hand, India — strategically protecting its sovereignty — must continue to protect its farmers from likelihood of predatory practices of select global conglomerates who may vie for a lucrative ‘Desi’ pie without investing in sustainable market infrastructure creation, anchoring agri value chain financing and being a partner in welfare schemes that upend ‘Ease of Living’ for our farming community, the report stressed.

Significantly, India has trumped global giants in milk production between 2015-2024.

In the year 2015, India's total milk production stood close to 155.5 million tonnes (EU 154.6 MT and US 94.6 MT).

When it comes to the pharmaceuticals market, India has been a cornerstone of the global supply chain for affordable, high-quality, essential medicines, particularly life saving oncology drugs, antibiotics, and chronic diseases' treatments.

“In the generic drug market, India supplies nearly 35 per cent of the pharmaceutical needs of the US. If the US shifts manufacturing and API production to other countries or domestic facilities, it will take minimum 3-5 years for meaningful capacity,” said the report.

In the US, health expenditure per person per annum is around $15,000, and hence with 35 per cent, India’s share in generic drugs tariff is going to impact US citizens significantly.

“Putting tariff on India pharma exports hurts the US objective of reducing the size of general government and goes against the objectives of DOGE. The US national health expenditures is 17.6 per cent of the GDP and the government-sponsored Medicare and Medicaid account for 36 per cent of the total expenditure,” said the report, adding that higher price of affordable medicines increase both expenditure under Medicare and Medicaid and also the out-of-pocket expenditure of private citizens.

Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Open in App

Related Stories

InternationalMike Pence says US companies and consumers paying the cost of Trump’s tariffs

TechnologyMike Pence says US companies and consumers paying the cost of Trump’s tariffs

Entertainment'Udaipur Files' releases after multiple delays; Kanhaiya Lal's son says, "it's "not against any religion"

EntertainmentPriyanka Chopra treats with some awe-worthy glimpses of little Malti with her family

BusinessIndia's Rising Pastry Stars Shine at 4th Junior Pastry India Cup 2025, APCA Gurgaon Wins title

Business Realted Stories

BusinessBhumi and Samiksha Pednekar Launch Backbay: A New Chapter in Sustainable Hydration

BusinessMike Pence says US companies and consumers paying the cost of Trump’s tariffs

BusinessHK-listed IVD Medical Invests HK$149M in Ethereum through HashKey Exchange

BusinessDeepa Singh appointed as Vice President & Head - HR & Admin at Exide Industries Ltd.

BusinessWhat is Universal Banking? RBI Grants This License to a Bank for the First Time in 11 Years